{"entity":{"id":"stephenson-oklahoma","kind":"institution","name":"Stephenson Cancer Center, OU Health","aka":[],"tldr":"Oklahoma's only NCI-designated centre, consistently among the top enrollers in NRG gynaecologic trials and home of the SOLO1 and MIRASOL ovarian cancer lead investigator.","summary":"NCI-designated in 2018, Stephenson Cancer Center is the only NCI centre in Oklahoma and serves a state with large American Indian populations. Its gynaecologic oncology group is one of the most productive in the NCI's National Clinical Trials Network: Kathleen Moore led SOLO1, which established olaparib maintenance in newly diagnosed BRCA-mutated ovarian cancer, and MIRASOL, which confirmed the folate receptor alpha ADC mirvetuximab soravtansine in platinum-resistant disease. The Oklahoma Tobacco Research Center and TSET-funded cancer control programmes address the state's high smoking rates, and the centre runs an active phase 1 programme.","asOf":"2026-09-09","links":[{"label":"Stephenson Cancer Center","url":"https://www.ouhealth.com/stephenson-cancer-center/"},{"label":"Clinical trials","url":"https://www.ouhealth.com/stephenson-cancer-center/research-clinical-trials/"}],"tags":[],"related":[],"cancers":["ovarian","cervical","endometrial"],"sections":[],"technologies":["parp-inhibitor","adc"],"targets":["parp","folr1"],"drugs":["olaparib","mirvetuximab-soravtansine"],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["kathleen-moore"],"bottlenecks":["b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Oklahoma City, OK","country":"US","lat":35.48,"lng":-97.497,"institutionType":"cancer-center","website":"https://www.ouhealth.com/stephenson-cancer-center/","nci":"clinical","university":"University of Oklahoma","programs":["Gynaecologic oncology trials (NRG)","Ovarian cancer (PARP inhibitors, FRα ADCs)","Tobacco research"]},"route":"/institutions/stephenson-oklahoma/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"target":[{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/"}],"person":[{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","route":"/people/kathleen-moore/"}],"bottleneck":[{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}]}}